Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)

ID Number 16-1112

Principal Investigator(s)
Yousaf Ali

Department(s) or Division(s)
Rheumatology

Description

The purpose of this research study to find out the link between rheumatoid arthritis (RA) and vascular inflammation. Also to learn whether increased systemic inflammation causes cardiovascular diseases (CVD), and which treatment approach, TNF inhibitors or Triple Therapy, will have a better effect on vascular inflammation and controlling rheumatoid arthritis disease activity. TNF inhibitors refer to the drugs Humira and Enbrel. Triple therapy means a combination of the drugs Plaquenil, Methotrexate, and Sulfasalazine.

Adalimumab (Humira), Etanercept (Enbrel), Hydroxychloroquine sulfate (Plaquenil), Leflunomide (Arava), Methotrexate (Rheumatrex, Trexall), and Sulfasalazine (Azulfidine) are approved by the U.S. Food and Drug Administration (FDA) to treat RA, but they are not approved by the FDA to treat CVD.

Subjects must have RA with an inadequate response to Methotrexate monotherapy to participate in this study.

About 200 subjects will take part in this study.



Contact Information
Garnette Mason
(212) 241-4824
garnette.mason@msms.edu

Recruiting Patients: Yes